DRUGS

简称 DRUGS ·NEW ZEALAND ·出版周期 Monthly ·年均收录 144 篇

14.4

最新影响因子

1.70%

自引率

较难

投稿难度

一般,3-8周

审稿周期

期刊简介

DRUGS是一本国际知名的药学领域学术期刊，ISSN号为0012-6667，由Adis International Ltd出版，出版地为新西兰，出版周期为半月刊。该期刊的影响因子较高，具体数值需查阅最新JCR报告，属于非OA（开放获取）期刊，并被SCI收录，中科院分区通常位于医学或药学领域的较高分区（具体分区需根据年度更新确认）。其发文特点集中于药物研发、临床药理学、药物治疗学及药物经济学等领域，尤其关注创新药物的临床评价与合理用药。杂志以高质量综述和原创研究为主，学术声誉良好，但需注意其审稿周期可能较长，且作为非OA期刊，读者需订阅才能获取全文。总体而言，DRUGS是药学领域的权威期刊，适合从事药物研究和临床实践的学者投稿与参考。

影响因子趋势

近期发表

Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies 2026-09-16

Doravirine/Islatravir: First Approval 2026-09-12

GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis 2026-09-12

Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026-09-12

Safety Profile of the Non-steroidal Anti-inflammatory Drug Celecoxib in the Short-Term Management of Acute Non-cancer Pain: A Systematic Review with Meta-analysis of Randomised Controlled Trials 2026-09-12

Anbenitamab: First Approval 2026-09-12

Atacicept: First Approval 2026-09-09

Pivekimab Sunirine: First Approval 2026-09-04

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes 2026-09-01

Vepdegestrant: First Approval 2026-08-28